These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1019 related items for PubMed ID: 19861722

  • 1. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor.
    Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R, Reedtz-Runge S.
    J Biol Chem; 2010 Jan 01; 285(1):723-30. PubMed ID: 19861722
    [Abstract] [Full Text] [Related]

  • 2. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
    Coopman K, Wallis R, Robb G, Brown AJ, Wilkinson GF, Timms D, Willars GB.
    Mol Endocrinol; 2011 Oct 01; 25(10):1804-18. PubMed ID: 21868452
    [Abstract] [Full Text] [Related]

  • 3. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.
    Runge S, Thøgersen H, Madsen K, Lau J, Rudolph R.
    J Biol Chem; 2008 Apr 25; 283(17):11340-7. PubMed ID: 18287102
    [Abstract] [Full Text] [Related]

  • 4. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
    López de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D.
    J Biol Chem; 2003 Mar 21; 278(12):10195-200. PubMed ID: 12524435
    [Abstract] [Full Text] [Related]

  • 5. Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.
    West GM, Willard FS, Sloop KW, Showalter AD, Pascal BD, Griffin PR.
    PLoS One; 2014 Mar 21; 9(9):e105683. PubMed ID: 25180755
    [Abstract] [Full Text] [Related]

  • 6. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
    Mann RJ, Nasr NE, Sinfield JK, Paci E, Donnelly D.
    Br J Pharmacol; 2010 Aug 21; 160(8):1973-84. PubMed ID: 20649595
    [Abstract] [Full Text] [Related]

  • 7. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
    Al-Sabah S, Donnelly D.
    Br J Pharmacol; 2003 Sep 21; 140(2):339-46. PubMed ID: 12970080
    [Abstract] [Full Text] [Related]

  • 8. Structural basis for ligand recognition of incretin receptors.
    Underwood CR, Parthier C, Reedtz-Runge S.
    Vitam Horm; 2010 Sep 21; 84():251-78. PubMed ID: 21094903
    [Abstract] [Full Text] [Related]

  • 9. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R).
    Yang D, de Graaf C, Yang L, Song G, Dai A, Cai X, Feng Y, Reedtz-Runge S, Hanson MA, Yang H, Jiang H, Stevens RC, Wang MW.
    J Biol Chem; 2016 Jun 17; 291(25):12991-3004. PubMed ID: 27059958
    [Abstract] [Full Text] [Related]

  • 10. Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain.
    Moon MJ, Lee YN, Park S, Reyes-Alcaraz A, Hwang JI, Millar RP, Choe H, Seong JY.
    J Biol Chem; 2015 Feb 27; 290(9):5696-706. PubMed ID: 25561730
    [Abstract] [Full Text] [Related]

  • 11. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
    Runge S, Schimmer S, Oschmann J, Schiødt CB, Knudsen SM, Jeppesen CB, Madsen K, Lau J, Thøgersen H, Rudolph R.
    Biochemistry; 2007 May 15; 46(19):5830-40. PubMed ID: 17444618
    [Abstract] [Full Text] [Related]

  • 12. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
    Graziano MP, Hey PJ, Strader CD.
    Recept Channels; 1996 May 15; 4(1):9-17. PubMed ID: 8723643
    [Abstract] [Full Text] [Related]

  • 13. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.
    Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM.
    J Biol Chem; 2012 Feb 03; 287(6):3642-58. PubMed ID: 22147710
    [Abstract] [Full Text] [Related]

  • 14. Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function.
    Van Eyll B, Göke B, Wilmen A, Göke R.
    Peptides; 1996 Feb 03; 17(4):565-70. PubMed ID: 8804062
    [Abstract] [Full Text] [Related]

  • 15. α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4.
    Oddo A, Mortensen S, Thøgersen H, De Maria L, Hennen S, McGuire JN, Kofoed J, Linderoth L, Reedtz-Runge S.
    Biochemistry; 2018 Jul 17; 57(28):4148-4154. PubMed ID: 29877701
    [Abstract] [Full Text] [Related]

  • 16. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity.
    Wilmen A, Göke B, Göke R.
    FEBS Lett; 1996 Nov 25; 398(1):43-7. PubMed ID: 8946950
    [Abstract] [Full Text] [Related]

  • 17. Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation.
    Moon MJ, Kim HY, Park S, Kim DK, Cho EB, Park CR, You DJ, Hwang JI, Kim K, Choe H, Seong JY.
    J Biol Chem; 2012 Feb 03; 287(6):3873-84. PubMed ID: 22105074
    [Abstract] [Full Text] [Related]

  • 18. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
    Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J.
    J Biol Chem; 1997 Aug 22; 272(34):21201-6. PubMed ID: 9261127
    [Abstract] [Full Text] [Related]

  • 19. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.
    Runge S, Wulff BS, Madsen K, Bräuner-Osborne H, Knudsen LB.
    Br J Pharmacol; 2003 Mar 22; 138(5):787-94. PubMed ID: 12642379
    [Abstract] [Full Text] [Related]

  • 20. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B.
    J Biol Chem; 1993 Sep 15; 268(26):19650-5. PubMed ID: 8396143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.